MARKET

EYPT

EYPT

Eyepoint Pharmac
NASDAQ
16.16
-0.31
-1.88%
After Hours: 15.85 -0.31 -1.92% 16:55 04/25 EDT
OPEN
16.26
PREV CLOSE
16.47
HIGH
16.26
LOW
15.51
VOLUME
749.63K
TURNOVER
0
52 WEEK HIGH
30.99
52 WEEK LOW
5.67
MARKET CAP
805.27M
P/E (TTM)
-8.8806
1D
5D
1M
3M
1Y
5Y
Over $10M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying
U.S. Stocks closed higher on Monday. There were a few notable insider trades in MasterCraft Boat Holdings, Inc. And Steel Connect. Insider purchases indicate confidence in the company’s prospects or that they view the stock as a bargain. EyePoint Pharmaceuticals and Lindblad Expeditions Holdings made recent notable insider purchases.
Benzinga · 3d ago
Eyepoint Pharmac: Initial statement of beneficial ownership of securities
Press release · 3d ago
Weekly Report: what happened at EYPT last week (0415-0419)?
Weekly Report · 4d ago
Baird sees weakness in Ocular shares "overdone" in wake of Phase 1 data
Baird sees weakness in Ocular shares as "overdone" and remains bullish on the company's opportunity in wet AMD. The investment firm said results from the Phase 1 Helios study of Axpaxli showed no notable safety issues. Baird maintained its outperform rating on the stock with a price target of $18.
Seeking Alpha · 6d ago
Buy Recommendation: EyePoint Pharmaceuticals’ Promising Outlook with EYP-1901 for Diabetic Retinopathy and AMD
TipRanks · 04/19 10:45
Noteworthy Thursday Option Activity: GPC, SNPS, EYPT
NASDAQ · 04/18 19:20
Veru, EyePoint Pharmaceuticals, SINTX Technologies among healthcare movers
Seeking Alpha · 04/18 14:00
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint Pharmaceuticals, Inc. Granted non-statutory stock options to new employees as inducement awards. The company is a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The stock options were granted outside of the company's 2023 incentive plan.
Barchart · 04/16 06:00
More
About EYPT
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the business of developing and commercializing ophthalmic products for the treatment of eye diseases. The Company's pipeline leverages its Durasert technology (Durasert) for sustained intraocular drug delivery, including delivery of EYP-1901, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases. Its additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. EYP-1901 is presently in Phase 2 clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), no proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The Company’s other products include YUTIQ, and DEXYCU.

Webull offers Eyepoint Pharmaceuticals Inc stock information, including NASDAQ: EYPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EYPT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EYPT stock methods without spending real money on the virtual paper trading platform.